SR9009 – (1379686-30-2)

SR9009, also known as Stenabolic, is a synthetic REV-ERB agonist initially developed by Professor Thomas Burris at the Scripps Research Institute. It has been shown to increase exercise capacity in mice by boosting mitochondrial biogenesis in skeletal muscle. This effect is primarily attributed to the activation of Rev-ErbA-α, which enhances the body’s metabolic activity and promotes the creation of new mitochondria while clearing out defective ones.

Recent studies have demonstrated that SR9009 can significantly enhance running capacity in mice, with treated animals showing a 50% increase in both time and distance. This improvement is accompanied by a shift in gene expression patterns that resemble those of an athlete’s muscle, indicating a transformation towards a more oxidative, endurance-oriented muscle phenotype.

Furthermore, research has revealed that SR9009’s cardioprotective effects are not solely dependent on REV-ERB. In mice with cardiomyocyte-specific REV-ERBα/β double knockout (cDKO), SR9009 retained its ability to protect against pressure overload-induced heart failure, suggesting the involvement of additional mechanisms beyond REV-ERB signaling.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/SR9009
https://pubchem.ncbi.nlm.nih.gov/compound/57394020
https://www.medchemexpress.com/SR9009.html
https://www.medkoo.com/products/14012
https://pmc.ncbi.nlm.nih.gov/articles/PMC9329699/
https://www.scripps.edu/newsandviews/e_20130729/burris.html